Nanoparticles and the mononuclear phagocyte system: Pharmacokinetics and applications for inflammatory diseases

Current Rheumatology Reviews

Volumn 10, Issue 1, 2014, Pages 22-34

  Song, Gina ^a   Petschauer, Jennifer S ^a   Madden, Andrew J ^a   Zamboni, William C ^a,b,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Carolina Center of Cancer Nanotechnology Excellence   (United States)

Author keywords

Drug targeting; Inflammatory diseases; Macrophages; Mononuclear phagocyte system; Nanoparticles; Pharmacokinetics

Indexed keywords

NANOPARTICLE; VACCINE;

ADSORPTION; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; CELL INTERACTION; DEGENERATIVE DISEASE; ENDOCYTOSIS; GLOMERULONEPHRITIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; IRRITABLE COLON; MONONUCLEAR PHAGOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; OPSONIZATION; PARTICLE SIZE; RHEUMATOID ARTHRITIS; ANIMAL; DRUG DELIVERY SYSTEM; INFLAMMATION; PHARMACOKINETICS; PHYSIOLOGY; PROCEDURES; RHEUMATIC DISEASES; TREATMENT OUTCOME;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; PHARMACOKINETICS; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 84911410432     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/1573403X10666140914160554     Document Type: Article

References (133)

1. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS nano 2009; 3(1):16-20.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2(12):751-60.
3. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clin PharmacolTher 2007; 83(5):761-9.
4. Official website of the United States National Nanotechnology Initiative [homepage on the Internet]. White House Office of Science and Technology Policy [updated 2012 January 10; cited 2013 December 20]. Available from: http://www.nano.gov/nanotech-101/nanotechnology-facts
5. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin cancer res 2005; 11(23): 8230-4.
6. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008; 13(3): 248-60.
7. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001; 53(2): 283-318.
8. Colville-Nash P, Scott D. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51(7): 919-25.
9. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002; 4(Suppl 3): S81-S90.
10. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011; 2: 281-98.
11. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clinl Oncol 2010; 7(11): 653-64.
12. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 2000; 65(1): 271-84.
13. Pinto-Alphandary H, Balland O, Laurent M, Andremont A, Puisieux F, Couvreur P. Intracellular visualization of ampicillinloaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharm Res 1994; 11(1): 38-46.
14. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996; 14(17): 1677-85.
15. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1): 71-8.
16. Majno G, Joris I. Cells, tissues, and disease: principles of general pathology. Oxford University Press: New York 2004.
17. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010; 140(6): 771-6.
18. Barrera P, Blom A, Van Lent PL*et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis & Rheum 2000; 43(9):1951-9.
19. Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005; 26(35): 7260-75.
20. Dams E, Reijnen M, Oyen W*et al. Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc- HYNIC IgG. Ann Surg 1999; 229(4): 551.
21. Metselaar JM, Wauben MH, Wagenaar-Hilbers J, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis & Rheum 2003; 48(7): 2059-66.
22. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60(15): 1615-26.
23. Koo OMY, Rubinstein I, Önyüksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res 2011; 28(4): 776-87.
24. Yokoyama M, Okano T. Targetable drug carriers: present status and a future perspective. Adv Drug Deliv Rev 1996; 21(2): 77-80.
25. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422(6927): 37-44.
26. Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 2004; 93(8): 1980-92.
27. Ulbrich W, Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J R Soc Interface 2010; 7(Suppl 1): S55-S66.
28. Peltz G. Inflammatory disease: where immunology and adhesion meet? Curr Opin Biotechnol 1993; 4(6): 745-50.
29. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004; 56(8): 1205-17.
30. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003; 24(12): 640-7.
31. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2(10): 750-63.
32. Jung H, Yang T, Lasagna MD, Shi J, Reinhart GD, Cremer PS. Impact of hapten presentation on antibody binding at lipid membrane interfaces. Biophys J 2008; 94(8): 3094-103.
33. Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 2010; 151(2): 458-65.
34. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2(8): 469-78.
35. Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 2012; 22(3): 177-92.
36. Ritschel WA, Kearns GL. Handbook of basic pharmacokinetics-- including clinical applications. : American Pharmacists Association Washington, DC 2004.
37. Yurkovetskiy A, Hiller A, Syed S*et al. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Mol Pharm 2004; 1(5): 375-82.
38. Zolnik BS, Stern ST, Kaiser JM*et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Disposition 2008; 36(8): 1709-15.
39. Zamboni WC, Edwards RP, Mountz JM, Eiseman JL, Basse PH, Zamboni BA*et al. The development of liposomal and nanoparticle anticancer agents: methods to evaluate the encapsulated and released drug in plasma and tumor and phenotypic probes for pharmacokinetic [PK] and pharmacodynamic [PD] disposition. Proceedings of the 2007 NSTI Nanotechnology Conference; 2007; 1582: 20-24.
40. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol pharm 2008; 5(4): 487-95.
41. Li S, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol pharm 2008; 5(4): 496-504.
42. Caron W, Song G, Kumar P, Rawal S, Zamboni W. Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier- Mediated Anticancer Agents. Clin Pharmacol Ther 2012; 91(5): 802-12.
43. Caron WP, Rawal S, Song G, Kumar P, Lay JC, Zamboni WC. Bidirectional Interaction Between Nanoparticles and Cells of the Mononuclear Phagocytic System published in "Handbook of immunological properties of engineered nanomaterials",edited by Dobrovolskaia MA and McNeil SE, World Scientific publishing Inc, Singapore, February 2013.
44. ®]. J Liposome Res 1994; 4(1): 667-87.
45. Choi M, Stanton-Maxey KJ, Stanley JK*et al. A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano lett 2007; 7(12): 3759-65.
46. Wilhelmi V, Fischer U, van Berlo D, Schulze-Osthoff K, Schins RP, Albrecht C. Evaluation of apoptosis induced by nanoparticles and fine particles in RAW 264.7 macrophages: facts and artefacts. Toxicol in vitro 2012; 26(2): 323-34.
47. Bhattacharjee S, de Haan LH, Evers NM*et al. Role of surface charge and oxidative stress in cytotoxicity of organic monolayercoated silicon nanoparticles towards macrophage NR8383 cells. Part fibre toxicol 2010; 7(1): 25.
48. Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert opin drug deliv 2010; 7(9): 1063-77.
49. Hanley C, Thurber A, Hanna C, Punnoose A, Zhang J, Wingett DG. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale res lett 2009; 4(12):1409-20.
50. Bookman M. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 2005;15(s3):212-20.
51. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int j Cancer 1995; 61(5): 716-21.
52. Zamboni WC, Maruca LJ, Strychor S et al. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 [SCKD602] and monocytes in patients with refractory solid tumors. J Liposome Res 2011; 21[2]:158-65.
53. Phillips NC. Kupffer cells and liver metastasis. Cancer Metastasis Rev 1989; 8(3): 231-52.
54. Moghimi SM, Hunter AC. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm Res 2001; 18(1): 1-8.
55. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998; 15(1):.
56. Torchilin VP, Shtilman MI, Trubetskoy VS, Whiteman K, Milstein AM. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. BBA-Biomembranes 1994; 1195(1): 181-84.
57. Woodle MC, Lasic DD. Sterically stabilized liposomes. BBA Biomembranes 1992; 1113(2): 171-99.
58. Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307(1): 93-102.
59. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere- serum interface: implications for stealth nanoparticle engineering. ACS nano 2010; 4(11): 6629-38.
60. Hamad I, Hunter A, Szebeni J, Moghimi SM. Poly [ethylene glycol] s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2- dependent process. Mol Immunol 2008; 46(2): 225-32.
61. Moghimi SM, Hamad I, Andresen TL, Jørgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipidmethoxy [polyethylene glycol] conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. The FASEB journal 2006; 20(14): 2591-3.
62. Moghimi S, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42(6): 463-78.
63. Parodi A, Quattrocchi N, van de Ven*et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess celllike functions. Nat Nanotechnology 2013; 8(1): 61-68.
64. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal" Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles. Science 2013; 339(6122): 971-5.
65. Vonarbourg A, Passirani C, Saulnier P, Benoit J. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006; 27(24): 4356-73.
66. França A, Aggarwal P, Barsov EV, Kozlov SV, Dobrovolskaia MA, González-Fernández Á. Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine 2011; 6(7): 1175-88.
67. Gough PJ, Gordon S. The role of scavenger receptors in the innate immune system. Microb Infect 2000; 2(3): 305-11.
68. Guo C, Yi H, Yu X*et al. Absence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response. Immunol Cell Biol 2011; 90(1): 101-8.
69. Doshi N, Mitragotri S. Macrophages recognize size and shape of their targets. PLoS One 2010; 5(4): e10051.
70. Thomas SN, van der Vlies, André J*et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 2011; 32(8): 2194-203.
71. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol pharma 2008; 5(4): 505-15.
72. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1984; 2(1): 283-318.
73. Szebeni J, Bedőcs P, Rozsnyay Z*et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2012; 8(2): 176-184.
74. Roerdink F, Wassef NM, Richardson EC, Alving CR. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. BBA-Biomembranes 1983; 734(1): 33-9.
75. Liu F, Liu D. Serum independent liposome uptake by mouse liver. BBA-Biomembranes 1996; 1278(1):5-11.
76. Jeon S, Lee J, Andrade J, De Gennes P. Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. J Colloid Interface Sci 1991; 142(1): 149-58.
77. Nagaoka S, Mori Y, Takiuchi H*et al. Polymers as biomaterials. SW Shalaby, AS Hoffman, BD Ratner and TA Horbett, Ed 1984; 361.
78. Nagaoka S, Mori Y, Takiuchi H, Yokota K, Tanzawa H, Nishiumi S. Interaction between blood components and hydrogels with poly [oxyethylene] chains. Polymers as biomaterials: Springer; 1985. p. 361-374.
79. Senior J. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1986; 3(2):123-93.
80. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11(3): 402-6.
81. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposome- complement interactions in rat serum: implications for liposome survival studies. BBA-Biomembranes 1994; 1191(1): 43-51.
82. Harashima H, Hiraiwa T, Ochi Y, Kiwada H. Size dependent liposome degradation in blood: in vivo/in vitro correlation by kinetic modeling. J Drug Target 1995; 3(4): 253-61.
83. Yu B, Hailman E, Wright SD. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997; 99(2): 315.
84. Harashima H, Huong T, Ishida T, Manabe Y, Matsuo H, Kiwada H. Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharm Res 1996; 13(11): 1704-9.
85. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A 2006; 103(13): 4930-4.
86. Gratton SE, Ropp PA, Pohlhaus PD*et al. The effect of particle design on cellular internalization pathways. PNAS 2008; 105(33): 11613-8.
87. Brochet B, Deloire M, Touil T*et al. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE. Neuroimage 2006;32(1):266-274.
88. Deloire MS, Touil T, Brochet B, Dousset V, Caillé J, Petry KG. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed Tcell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler 2004; 10(5): 540-8.
89. Davignon JL, Hayder M, Baron M*et al. Targeting monocytes/ macrophages in the treatment of rheumatoid arthritis. Rheumatology [Oxford]. 2013; 52(4): 590-8.
90. Davidsen J, Jørgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. BBABiomembranes 2003; 1609(1):95-101.
91. Vermehren C, Kiebler T, Hylander I, Callisen TH, Jørgensen K. Increase in phospholipase A2 activity towards lipopolymercontaining liposomes. BBA-Biomembranes 1998; 1373(1): 27-36.
92. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23): 2205-19.
93. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 1997; 40(1): 5-18.
94. Ulmansky R, Turjeman K, Baru M*et al. Glucocorticoids in nanoliposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release 2012; 160(2): 299-305.
95. Prabhu P, Shetty R, Koland M*et al. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomedicine 2012; 7: 177-86.
96. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13(3): 470-511.
97. Johnson RJ, Gretch DR, Yamabe H*et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328(7): 465-70.
98. Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol 2006; 28(2): 97-107.
99. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10(2): 413-24.
100. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol 2011; 22(1): 21-7.
101. Chafin CB, Reilly CM. MicroRNAs implicated in the immunopathogenesis of lupus nephritis. Clin Dev Immunol 2013; 2013: 430239.
102. Kitamoto K, Machida Y, Uchida J*et al. Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci 2009; 111(3): 285-92.
103. Hickman SE, El Khoury J. The neuroimmune system in Alzheimer's disease: the glass is half full. J Alzheimers Dis 2013; 33 Suppl 1: S295-302.
104. Kotter MR, Zhao C, van Rooijen N, Franklin RJ. Macrophagedepletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005; 18(1): 166-175.
105. Vogel DY, Vereyken EJ, Glim JE*et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 2013; 10(35).
106. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009; 29(43): 13435-44.
107. Medina-Contreras O, Geem D, Laur O*et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest 2011; 121(12): 4787-95.
108. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013; 62(11): 1653-64.
109. Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release 2012; 161(2): 235-46.
110. Mahajan N, Sakarkar D, Manmode A, PathakV, Ingole R, Dewade D. Biodegradable Nanoparticles for Targeted Delivery in Treatment of Ulcerative Colitis. Adv Sci Lett 2011; 4(2): 349-56.
111. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
112. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010 ; 7(2): 77-86.
113. Chono S, Tauchi Y, Deguchi Y, Morimoto K. Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice. J Drug Target 2005; 13(4): 267-76.
114. Chono S, Tauchi Y, Morimoto K. Pharmacokinetic analysis of the uptake of liposomes by macrophages and foam cells in vitro and their distribution to atherosclerotic lesions in mice. Drug Metab Pharmacokinet 2006; 21(1): 37-44.
115. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013; 3: 13.
116. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006; 6(4): 662-8.
117. Tafaghodi M, Saluja V, Kersten GF*et al. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics. Vaccine 2012; 30(36): 5341-8.
118. Mitragotri S, Yoo JW. Designing micro- and nano-particles for treating rheumatoid arthritis. Arch Pharm Res. 2011; 34(11): 1887-97.
119. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV. Folate coupled poly[ethyleneglycol] conjugates of anionic poly[amidoamine] dendrimer for inflammatory tissue specific drug delivery. J Biomed Mater Res A. 2007; 82(1): 92-103.
120. Vanniasinghe AS, Bender V, Manolios N. The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum 2009; 39(3): 182-96.
121. Liang LS, Wong W, Burt HM. Pharmacokinetic study of methotrexate following intra-articular injection of methotrexate loaded poly[L-lactic acid] microspheres in rabbits. J Pharm Sci 2005; 94(6): 1204-15.
122. Filippini G, Brusaferri F, Sibley WA*et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (4): CD001331.
123. Linker RA, Weller C, Lühder F*et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol 2008; 211(2): 397-406.
124. Hu W, Metselaar J, Ben LH*et al. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One 2009; 4(1): e4151.
125. Bernardi A, Frozza RL, Meneghetti A*et al. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine 2012; 7: 4927-42.
126. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005; 315(1): 196-202.
127. Pertuit D, Moulari B, Betz T*et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 2007; 123(3): 211-8.
128. Hattori Y, Sakaguchi M, Maitani Y. Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells. Biol Pharm Bull 2006; 29(7): 1516-20.
129. Mansouri S, Cuie Y, Winnik F*et al. Characterization of folatechitosan- DNA nanoparticles for gene therapy. Biomaterials. 2006; 27(9): 2060-5.
130. Naor D, Nedvetzki S. CD44 in rheumatoid arthritis. Arthritis Res Ther. 2003; 5(3): 105-15.
131. Schmitt F, Lagopoulos L, Käuper P*et al. Chitosan-based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints. J Control Release 2010; 144(2): 242-50.
132. Sakhalkar HS, Dalal MK, Salem AK*et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci U S A. 2003; 100(26): 15895-900.
133. Minaguchi J, Oohashi T, Inagawa K, Ohtsuka A, Ninomiya Y. Transvascular accumulation of Sialyl Lewis X conjugated liposome in inflamed joints of collagen antibody-induced arthritic [CAIA] mice. Arch Histol Cytol. 2008; 71(3): 195-203.